LIPO

Lipella Pharmaceuticals Inc. (LIPO) | Rumor.io

Lipella Pharmaceuticals

LIPO

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)0%

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)536.4K

Net income (annual)-5M

Social

What share of all stock conversation is about LIPO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Jun 23

Lipella Pharmaceuticals Inc. ($LIPO) has established a starter position at $1.19, considered a high-risk, high-reward investment.
The company is participating in a Phase 2 trial, with an estimated completion date in late June (NCT06233591).
The CEO is under criticism for their leadership, with some users expressing concerns about the company's moral compass and performance.

Generated by AI

Sentiment

Of the messages about LIPO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	79.03% -0.94
Bearish	—	—	—	20.97% +0.94

Bullish· Feb 11

$LIPO is showing strong strength and is expected to be a multi-day runner.
$LIPO has seen significant buying activity, including a "monster buy" at $4.50 and a large buy order at $4.03.
$LIPO is expected to break through key resistance levels, including the recent high, and potentially reach $8.5 or even $10, with strong volume supporting its upward momentum.

Bearish· Feb 11

The author believes $LIPO is heavily naked shorted and could be a good squeeze candidate.
The company's upcoming S3 offering could lead to dilution, potentially setting the stage for a backside PR squeeze.
The author thinks $LIPO is being held ransom by bid whackers and shorts, and expects it to drop if it can't get above $5.50.

Generated by AI

Topics

Of the messages about LIPO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	83.65%
Controversies	—	—	—	0.96%
Earnings	—	—	—	0.96%
Macro	—	—	—	0%
Technical Analysis	—	—	—	14.42%

Announcements· Feb 11

Lipella Pharmaceuticals ($LIPO) reported positive topline Phase 2a results for LP-310 in treating oral lichen planus, showing statistically significant improvements across all key efficacy endpoints.
LP-310 demonstrated a strong safety profile with no serious adverse events, and 100% of patients completed the study.
Lipella Pharmaceuticals' LP-310 has gained FDA approval for an Expanded Access Program, making it the first FDA-approved therapy for oral lichen planus, a condition affecting around 6 million Americans.

Technical Analysis· Feb 11

* $LIPO is in a falling wedge pattern and needs to hold the 4.5 level to continue upward momentum.
* A break and re-test of 4.65 and then the VWAP is required for $LIPO to move up, with some traders reporting a 700%+ cost to borrow.
* $LIPO has a bull flag forming, but a topping tail under $5.5 is not a good look, and a break below this level could lead to a cliff to the 200DMA at $3.8.

Generated by AI

Community

Of the messages about LIPO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	18.7%
Newcomers	—	—	0%	81.3%

Regulars· Feb 11

The FDA approval for an Expanded Access Program for LP-310 has led to Lipella Pharmaceuticals' (+46.9% pre) $LIPO being at the top of the Prism MarketView Pharmaceuticals index.
Lipella's experimental drug, LP-310, has shown a strong safety profile and a 64% reduction in pain scores in a small study of 24 patients with oral lichen planus.
Lipella Pharmaceuticals will present the positive topline Phase 2a results for LP-310 in the treatment of oral lichen planus at the BIO CEO & Investor Conference on February 11, 2025.

Newcomers· Feb 12

Newcomers are discussing the liquidity of LIPO, noting a lack of volume during market hours and a significant amount of trading activity on $AIFF instead.
Some users are referencing a report by Maxim Group, which covers Lipella Pharmaceuticals Inc. and is available upon request via email.
The company $LIPO has announced positive preliminary data from its Phase 2A trial for its LP-310 oral rinse product.

Generated by AI

Also Discussed

Investors talking about LIPO also mention

#	Name	Attention
1	PaxMedica Inc.PXMD	0%0
2	ZAPP - Zapp Electric Vehicles Group Limited	——
3	Evaxion A/S American Depositary ShareEVAX	0%0
4	TWOU - 2U, Inc.	——
5	TCTM - TCTM Kids IT Education Inc.	——
6	STEC - Santech Holdings Limited	——
7	Tevogen Bio Holdings Inc.TVGN	0%0
8	Planet Image International Ltd. Class A Ordinary SharesYIBO	0%new
9	Silexion Therapeutics Corp.SLXN	0.03%-0.01
10	LianBioLIAN	0%0

Lipella Pharmaceuticals Inc.

Healthcare
Biotechnology

Lipella Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of new therapies for individuals suffering from debilitating urological disorders. The primary function of Lipella Pharmaceuticals is to create innovative treatment options that target unmet medical needs, particularly those related to bladder conditions. This involves drug delivery technologies and formulations designed to improve the efficacy and safety profiles of existing therapies. Lipella operates within the pharmaceutical and healthcare sectors, directly impacting patients and medical professionals seeking advanced solutions in urology. The company's research and development efforts aim at expanding treatment options to enhance the quality of life for patients who have limited therapeutic alternatives. In the financial market, Lipella Pharmaceuticals occupies a niche space within the biotech industry, offering potential growth pathways as it progresses through clinical trials and regulatory approvals. Its developments are closely monitored by stakeholders interested in medical innovation and potential breakthroughs in urological medicine.

Website

Location

7800 Susquehanna St.

Pittsburgh, PA, 15208

United States

Social

What share of all stock conversation is about LIPO?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% new	0% 0

Jun 23

Lipella Pharmaceuticals Inc. ($LIPO) has established a starter position at $1.19, considered a high-risk, high-reward investment.
The company is participating in a Phase 2 trial, with an estimated completion date in late June (NCT06233591).
The CEO is under criticism for their leadership, with some users expressing concerns about the company's moral compass and performance.

Generated by AI

Sentiment

Of the messages about LIPO that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	79.03% -0.94
Bearish	—	—	—	20.97% +0.94

Bullish· Feb 11

$LIPO is showing strong strength and is expected to be a multi-day runner.
$LIPO has seen significant buying activity, including a "monster buy" at $4.50 and a large buy order at $4.03.
$LIPO is expected to break through key resistance levels, including the recent high, and potentially reach $8.5 or even $10, with strong volume supporting its upward momentum.

Bearish· Feb 11

The author believes $LIPO is heavily naked shorted and could be a good squeeze candidate.
The company's upcoming S3 offering could lead to dilution, potentially setting the stage for a backside PR squeeze.
The author thinks $LIPO is being held ransom by bid whackers and shorts, and expects it to drop if it can't get above $5.50.

Generated by AI

Topics

Of the messages about LIPO that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	83.65%
Controversies	—	—	—	0.96%
Earnings	—	—	—	0.96%
Macro	—	—	—	0%
Technical Analysis	—	—	—	14.42%

Announcements· Feb 11

Lipella Pharmaceuticals ($LIPO) reported positive topline Phase 2a results for LP-310 in treating oral lichen planus, showing statistically significant improvements across all key efficacy endpoints.
LP-310 demonstrated a strong safety profile with no serious adverse events, and 100% of patients completed the study.
Lipella Pharmaceuticals' LP-310 has gained FDA approval for an Expanded Access Program, making it the first FDA-approved therapy for oral lichen planus, a condition affecting around 6 million Americans.

Technical Analysis· Feb 11

* $LIPO is in a falling wedge pattern and needs to hold the 4.5 level to continue upward momentum.
* A break and re-test of 4.65 and then the VWAP is required for $LIPO to move up, with some traders reporting a 700%+ cost to borrow.
* $LIPO has a bull flag forming, but a topping tail under $5.5 is not a good look, and a break below this level could lead to a cliff to the 200DMA at $3.8.

Generated by AI

Community

Of the messages about LIPO, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	100%	18.7%
Newcomers	—	—	0%	81.3%

Regulars· Feb 11

The FDA approval for an Expanded Access Program for LP-310 has led to Lipella Pharmaceuticals' (+46.9% pre) $LIPO being at the top of the Prism MarketView Pharmaceuticals index.
Lipella's experimental drug, LP-310, has shown a strong safety profile and a 64% reduction in pain scores in a small study of 24 patients with oral lichen planus.
Lipella Pharmaceuticals will present the positive topline Phase 2a results for LP-310 in the treatment of oral lichen planus at the BIO CEO & Investor Conference on February 11, 2025.

Newcomers· Feb 12

Newcomers are discussing the liquidity of LIPO, noting a lack of volume during market hours and a significant amount of trading activity on $AIFF instead.
Some users are referencing a report by Maxim Group, which covers Lipella Pharmaceuticals Inc. and is available upon request via email.
The company $LIPO has announced positive preliminary data from its Phase 2A trial for its LP-310 oral rinse product.

Generated by AI

Lipella Pharmaceuticals

Social

Jun 23

Sentiment

Bullish· Feb 11

Bearish· Feb 11

Topics

Announcements· Feb 11

Technical Analysis· Feb 11

Community

Regulars· Feb 11

Newcomers· Feb 12

Also Discussed

Lipella Pharmaceuticals Inc.

Company Information

Location

Also Discussed

Social

Jun 23

Sentiment

Bullish· Feb 11

Bearish· Feb 11

Topics

Announcements· Feb 11

Technical Analysis· Feb 11

Community

Regulars· Feb 11

Newcomers· Feb 12